VEYRA scores CRISPR guide-RNA candidates with a deterministic engine, layers interpretable AI reasoning on top, and renders the result as an interactive 3D structure — so every risk assessment is traceable, not a black-box number.
Deterministic core
Every score traces to PAM search, GC content, and seed-weighted mismatch analysis.
Every step below is real — click a dot or let it play through.
Ingest raw DNA input
Every score traces to a reproducible algorithm — PAM search, GC content, seed-weighted mismatch analysis. No black box.
Reasoning over the complete provided sequence, not a short isolated window — surfacing risk that short-window tools miss.
AI explains why a site is risky, tied to the underlying deterministic numbers — never a bare probability score.
Off-target risk isn't hypothetical — it's been documented in real published trials, and India currently has no dedicated gene-editing statute to fall back on. This is cited, published evidence, distinct from VEYRA's own illustrative research-prototype scores below.
Human medicine
In a first-in-human CRISPR-Cas9 sickle-cell study, patients' blood stem cells were edited outside the body and returned. The safety programme specifically investigates unintended genomic changes in these cells — the study did not establish that an off-target mutation harmed patients.
Source: New England Journal of Medicine
Cancer treatment
In the first-in-human CRISPR-Cas9 T-cell cancer trial, researchers detected chromosomal translocations in the manufactured cells, some persisting after infusion. The study found no evidence these translocations caused patient harm.
Source: PubMed Central (PMC); Nature
Livestock
CRISPR-edited pigs have been found with off-target mutations at other genomic locations; the animals were not shown to suffer an associated health problem. Separately, gene-edited hornless cattle were found to carry an undisclosed antibiotic-resistance marker from the editing process, surfacing only after regulatory review.
Source: Documented off-target case reports
India — regulatory gap
India has no dedicated gene-editing statute; oversight relies on advisory ICMR/DBT guidelines, not legally binding law. If an unintended genomic change occurred in an Indian trial today, there is currently no established compensation or liability pathway specific to CRISPR.
Source: ICMR/DBT guidelines; ART Act
Deterministic scoring, AI-explained risk, and an interactive 3D structure — one pipeline, fully traceable.
Run an analysis